An Introduction to Haematology
The field of haematology is far-reaching, encompassing many conditions of the blood and blood-forming organs, including anaemia, bleeding and coagulation disorders, sickle cell disease, congenital immunodeficiency diseases, transfusion medicine and haematopoietic stem cell transplantation. There continue to be many obstacles to gene therapy but ultimately this approach holds promise in inherited blood disorders. In addition, novel anticoagulant therapies, multiplexed sensing platforms and the application of artificial intelligence in diagnosis and monitoring are proving valuable in clotting disorders.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
From diagnosis to treatment: Understanding the role of complement in cold agglutinin disease
Watch leading haematology specialists provide an update on the pathophysiology, diagnosis and treatment for patients with cold agglutinin disease.
- Describe the pathophysiological features and diagnostic approaches in patients with cold agglutinin disease (CAD)
- Analyze current treatment approaches for CAD and their limitations
- Evaluate evidence-based novel approaches for the treatment of CAD
New Approaches to Allogeneic Hematopoietic Cell Transplantation
Oncology & Hematology Review (US). 2020;16(2):Online ahead of journal publication
**This manuscript has been accepted for publication, but not yet copyedited or typeset, and may be subject to minor changes during the production process.**
Steven Pipe, ASH 2020 – First Results from the HOPE-B Gene Therapy Trial
We had the pleasure to talk to Steven Pipe (University of Michigan, Ann Arbor, MI, USA) to discuss the use of gene therapy for the treatment of haemophilia B. The abstract ‘First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe […]
Precision medicine in RRMM: Understanding how the data can be applied to practice
Watch a panel of experts discuss the latest advances in the treatment of relapsed and/or refractory multiple myeloma and the potential for precision medicine.
- Describe the current challenges in the treatment of multiple myeloma and considerations for overcoming poor prognosis
- Discuss the efficacy and safety data of novel agents being investigated in patients with RRMM
- Describe approaches to selecting treatment for patients with RRMM and the potential for precision medicine
Efstathios Kastritis, EHA 2020: CYBORD in Amyloidosis and The ANDROMEDA Study
touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at EHA25 Virtual to discuss the ANDROMEDA study (NCT03201965), and the efficacy and safety of daratumumab in combination with CYBORD for the treatment of newly-diagnosed light chain amyloidosis. Questions: What are the major therapeutic […]
Paroxysmal nocturnal hemoglobinuria: from biology to bedside
Prof. Régis Peffault de Latour (French Reference Center for Aplastic Anemia and PNH, Saint-Louis Hospital, Paris, France) appraises the most important recent and emerging data, and discusses their potential impact on the clinical management of patients living with PNH.
- Discuss the current treatment landscape for PNH
- Describe the unmet medical needs for PNH with respect to current treatment options
- Summarize the evolving treatment landscape and future approaches for the management of PNH
George Goshua, EHA 2020: Endotheliopathy is Essential in COVID-19 Associated Coagulopathy
Dr George Goshua (Yale University School of Medicine, New Haven, CT, USA) shares with us his insights into the role of endotheliopathy in the development of coagulopathy in patients with COVID-19. Questions: 1. How common is coagulopathy in COVID-19 infection and who is at greatest risk? (0:03) 2. What is known about the role of […]
Luspatercept for Beta-thalassemia – A New Horizon?
European Oncology & Haematology. 2020;16(1):16-7 DOI: https://doi.org/10.17925/EOH.2020.16.1.16
The chronic anaemia of beta-thalassemia major (b-thal) results from defective erythropoiesis secondary to a genetic defect in haemoglobin synthesis.1 Consequently, patients with moderate-to-severe disease rely on blood transfusions to maintain an adequate level of haemoglobin.2 Over time, this causes an iron-overloaded state, in addition to the possible blood-borne infections resulting from repeated transfusions.3 The widespread use of iron […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!